Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Celldex Therapeutics, Inc

CLDX

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Last trade $27.99
Day change -$0.60 (-2.10%)
Day range $27.51 – $29.73
Volume 226,755
Market cap $2.25B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.25B
Price / earnings
—
Price / book
3.46×
Price / sales
14,212.68×
EV / sales
14,042.09×
EV / EBITDA
-6.71×

Profitability

Earnings per share
-$3.93
Return on assets
-42.83%
Return on equity
-47.59%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.97×
Quick ratio
10.97×
Cash ratio
0.45×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$259.74M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CLDX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$22K$15K$121K$0$730K$695K$1.18M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$22K$15K$121K$0$730K$695K$1.18M
Selling, general and administrative$14.84M$13.1M$11.45M$11.94M$10.69M$10.39M$10.82M$10.26M
Research and development$67.41M$67.54M$73M$75.33M$62.93M$54.2M$52.61M$46.94M
Total operating expenses$82.25M$80.65M$84.45M$87.27M$73.62M$64.59M$63.43M$57.2M
Operating income-$82.25M-$80.62M-$84.44M-$87.15M-$73.62M-$63.86M-$62.74M-$56.03M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$75.56M-$73.5M-$78.69M-$81.32M-$67.04M-$56.6M-$53.8M-$47.09M
Income taxes$0$0$0$0$0$0$0$0
Net income-$75.56M-$73.5M-$78.69M-$81.32M-$67.04M-$56.6M-$53.8M-$47.09M
Net income attributable to common shareholders-$75.56M-$73.5M-$78.69M-$81.32M-$67.04M-$56.6M-$53.8M-$47.09M
EBITDA-$81.09M-$79.72M-$83.58M-$86.34M-$72.79M-$62.98M-$61.87M-$55.21M
Basic earnings per share-$0.96-$0.94-$1.18-$1.22-$1.01-$0.85-$0.81-$0.71
Diluted earnings per share-$0.96-$0.94-$1.18-$1.22-$1.01-$0.85-$0.81-$0.71

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

Four biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.

GlobeNewswire Inc.

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex announced positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU), showing that up to 64% of patients remained angioedema-free seven months after treatment completion. The drug demonstrated rapid, significant, and durable improvements in angioedema symptoms, with potential to shift CSU treatment from symptom control to disease modification. Two Phase 3 trials enrolling 1,939 patients are ongoing with topline data expected in Q4 2026.

GlobeNewswire Inc.

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex announced positive Phase 1 results for CDX-622, a novel bispecific antibody targeting soluble SCF and TSLP for inflammatory diseases. The drug demonstrated rapid, dose-dependent reductions in serum tryptase indicative of mast cell depletion and was well-tolerated at all dose levels. CDX-622 is now being studied in Phase 1b for mild to moderate asthma, with plans for additional proof-of-concept studies in allergic rhinitis and food allergy.

GlobeNewswire Inc.

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Celldex Therapeutics successfully closed an underwritten public offering of 11,896,750 shares of common stock at $29.00 per share, generating approximately $345 million in gross proceeds. The underwriters exercised their full option to purchase an additional 1,551,750 shares. The offering was managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor as joint bookrunning managers.

GlobeNewswire Inc.

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Celldex Therapeutics priced an underwritten public offering of 10.3 million shares at $29.00 per share, expecting to raise approximately $300 million in gross proceeds. The company plans to use the funds for commercial readiness and launch of barzolvolimab for CSU treatment, clinical development of product candidates, and expansion of its bispecific antibody platform.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 11, 20191-for-15reverse split
Mar 7, 20081-for-12reverse split